CG Oncology, Inc. reports developments as a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec for bladder cancer. Its updates center on non-muscle invasive bladder cancer, including high-risk BCG-unresponsive, BCG-exposed and intermediate-risk disease settings, and describe clinical studies such as PIVOT-006, BOND-003 and CORE-008.
Recurring company news also covers financial results, FDA-related regulatory planning, clinical data presentations, manufacturing and BLA preparation, investor conference participation and research initiatives tied to NMIBC. The company's disclosures connect its operating cash position and development spending to the advancement of its bladder-sparing immunotherapy program.
CG Oncology (NASDAQ: CGON) has reported impressive updated data from its BOND-003 Cohort C trial for cretostimogene, showing a 41.8% complete response (CR) rate at 24 months in patients with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to BCG treatment.
The study demonstrated remarkable durability with 90% of 12-month responders remaining disease-free at 24 months. Among 110 heavily pretreated patients, 96.6% remained free from progression to muscle invasive disease at 24 months. The treatment showed excellent tolerability with no Grade 3 or greater treatment-related adverse events.
The company plans to initiate its BLA submission for cretostimogene in Q4 2025, positioning it as a potential breakthrough bladder-sparing therapeutic option.
CG Oncology (NASDAQ: CGON) has completed enrollment in its Phase 3 PIVOT-006 clinical trial, evaluating cretostimogene grenadenorepvec versus surveillance in intermediate-risk non-muscle invasive bladder cancer (IR NMIBC) patients. The study enrolled over 360 patients across 90+ sites, achieving completion nearly a year ahead of schedule.
The trial aims to address a significant unmet need, as IR NMIBC patients face recurrence rates of up to 70% with limited durable treatment options. Cretostimogene's novel approach works by selectively lysing tumor cells while activating anti-cancer immune responses, potentially offering a new treatment paradigm for bladder cancer patients.
CG Oncology (NASDAQ: CGON), a late-stage clinical biopharmaceutical company developing bladder-sparing therapeutics for bladder cancer, has announced upcoming presentations at two major investor conferences. The company's leadership team, including Chairman & CEO Arthur Kuan and President & COO Ambaw Bellete, will participate in fireside chats at:
- The Cantor Global Healthcare Conference on September 5, 2025, at 10:20am ET
- The Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 7:45am ET
Both presentations will be accessible via webcast on the company's investor relations website and will remain archived for approximately 90 days.
CG Oncology (NASDAQ: CGON) reported significant progress in Q2 2025, highlighted by impressive clinical results for their bladder cancer therapy cretostimogene grenadenorepvec. The company presented best-in-disease durability data showing a 75.5% complete response rate in the BOND-003 Cohort C trial, with 97.3% of patients free from disease progression at 24 months.
Key developments include initiating the CORE-008 Cohort CX trial combining cretostimogene with gemcitabine, and a favorable legal verdict against ANI Pharmaceuticals eliminating future royalty obligations. The company maintains a strong financial position with $661.1 million in cash, expecting to fund operations into H1 2028. Q2 resulted in a net loss of $41.4 million, with plans to initiate BLA submission in Q4 2025.
CG Oncology (NASDAQ: CGON) has secured a significant legal victory as a Delaware Superior Court jury unanimously ruled in the company's favor regarding a lawsuit filed by ANI Pharmaceuticals in March 2024. The Court determined that CG Oncology will not owe any future royalties on sales of cretostimogene grenadenorepvec, their investigational bladder cancer treatment.
The ruling eliminates a potential 5% royalty obligation on commercial sales and confirms no further payments are due to ANI Pharmaceuticals. This decision follows Judge Sheldon K. Rennie's July 16, 2025 ruling that legally barred ANI Pharmaceuticals from claiming royalties on future cretostimogene sales.
CG Oncology (NASDAQ: CGON), a late-stage clinical biopharmaceutical company specializing in bladder cancer therapeutics, has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, May 20, 2025, at 11:30 am ET in New York. Investors and interested parties can access the live audio webcast through CG Oncology's website investor relations section, with the replay remaining available for approximately 90 days after the presentation.
The company focuses on developing and commercializing a potential backbone bladder-sparing therapeutic for bladder cancer patients.CG Oncology (NASDAQ: CGON) has announced significant results for cretostimogene grenadenorepvec in treating bladder cancer at the 2025 American Urological Association Annual Meeting. The Phase 3 BOND-003 Cohort C study showed impressive durability with a 24-month complete response rate of 42.3% in high-risk non-muscle invasive bladder cancer (NMIBC) patients.
Key findings include:
- 75.5% complete response rate at any time
- 97.3% of patients remained free from progression to muscle invasive disease at 24 months
- 91.6% of responders remained cystectomy-free at 24 months
- Median duration of response of 28 months (ongoing)
Additionally, Cohort P demonstrated 90.5% high-grade recurrence-free survival at 3 and 9 months. The treatment showed excellent safety with no Grade 3 or greater treatment-related adverse events reported.